{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:04:07Z","timestamp":1782893047432,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.hoc.2016.11.005","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T16:51:59Z","timestamp":1490287919000},"page":"255-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Adult T-cell Leukemia\/Lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Christopher","family":"Dittus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Mark","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.hoc.2016.11.005_bib1","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2016.11.005_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/294268a0","article-title":"Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with S\u00e9zary T-cell leukaemia","volume":"294","author":"Poiesz","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2016.11.005_bib3","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","article-title":"Global epidemiology of HTLV-1 infection and associated diseases","volume":"24","author":"Proietti","year":"2005","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.hoc.2016.11.005_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/CMR.00063-09","article-title":"Epidemiology, treatment, and prevention of human T-cell leukemia virus 1-associated diseases","volume":"23","author":"Goncalves","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.hoc.2016.11.005_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1423-0410.1998.tb05416.x","article-title":"HTLV testing in blood transfusion","volume":"74","author":"Courouce","year":"1998","journal-title":"Vox Sang"},{"issue":"50","key":"10.1016\/j.hoc.2016.11.005_bib6","first-page":"915","article-title":"Human T-lymphotropic virus type I screening in volunteer blood donors \u2013 United States, 1989","volume":"39","author":"Centers for Disease Control and Prevention","year":"1990","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.hoc.2016.11.005_bib7","series-title":"IARC monographs on the evaluation of carcinogenic risks to humans, volume 100B","author":"International Agency for Research on Cancer","year":"2012"},{"key":"10.1016\/j.hoc.2016.11.005_bib8","first-page":"57","article-title":"Primary prevention of HTLV-1 in Japan","volume":"11","author":"Hino","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2016.11.005_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: A review and synthetic analysis","volume":"13","author":"De Martel","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2016.11.005_bib10","first-page":"1","article-title":"Incidence of adult T-cell leukemia\/lymphoma in nonendemic areas","volume":"16","author":"Yoshida","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib11","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2015-08-662593","article-title":"Polycomb-dependent epigenetic landscape in adult T-cell leukemia","volume":"127","author":"Fujikawa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib12","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2016-02-694885","article-title":"Tax fingerprint in adult T-cell leukemia","volume":"127","author":"Bazarbachi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib13","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"118","author":"Bazerbachi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.0507631103","article-title":"HTLV-1 basic leucine zipper factor gene mRNA supports proliferation of adult T\u00a0cell leukemia cells","volume":"103","author":"Satou","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2016.11.005_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2016.11.005_bib16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cas.12617","article-title":"Recent advances in the treatment of adult T-cell leukemia-lymphomas","volume":"106","author":"Utsunomiya","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.hoc.2016.11.005_bib17","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V99.2.634","article-title":"Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kB ligand on adult T-cell leukemia cells","volume":"99","author":"Nosaka","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib18","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/sj.leu.2404798","article-title":"Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kB in adult T-cell leukemia\/lymphoma","volume":"21","author":"Nadella","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2016.11.005_bib19","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2012-07-439109","article-title":"Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation","volume":"121","author":"Bellon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/(SICI)1096-8652(199811)59:3<242::AID-AJH11>3.0.CO;2-O","article-title":"Eosinophilia associated with adult T-cell leukemia: role of interleukin 5 and granulocyte-macrophage colony-stimulating factor","volume":"59","author":"Ogata","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2016.11.005_bib21","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdn696","article-title":"The international prognostic index predicts outcome in aggressive adult T-cell leukemia\/lymphoma: analysis of 126 patients from the international peripheral T-cell lymphoma project","volume":"20","author":"Suzumiya","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib23","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib24","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2006.11.013","article-title":"Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia\/lymphoma (ATLL)","volume":"31","author":"Takasaki","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2016.11.005_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.leukres.2006.10.017","article-title":"Clinical significance of a blood eosinophilia in adult T-cell leukemia\/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor","volume":"31","author":"Utsunomiya","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2016.11.005_bib26","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/blood.V122.21.4312.4312","article-title":"CD30 expression is associated with decreased survival in patients with acute and unfavorable chronic types of adult T-cell leukemia-lymphoma","volume":"122","author":"Campuzano-Zuluaga","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.thj.6200195","article-title":"A\u00a0prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma","volume":"3","author":"Hermine","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.hoc.2016.11.005_bib28","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alpha in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazerbachi","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib29","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1200\/JCO.2011.35.5578","article-title":"Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia\/lymphoma","volume":"29","author":"Hodson","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood.V93.1.278","article-title":"Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells","volume":"93","author":"Bazerbachi","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.thj.6200374","article-title":"Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"5","author":"Hermine","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.hoc.2016.11.005_bib32","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","article-title":"Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL)","volume":"113","author":"Kchour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib33","unstructured":"National Comprehensive Cancer Network. Non-Hodgkin\u2019s lymphomas (version 3.2016). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf. Accessed May 13, 2016."},{"key":"10.1016\/j.hoc.2016.11.005_bib34","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study (JCOG9801)","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib35","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib36","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib37","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1038\/bcj.2016.21","article-title":"Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma","volume":"6","author":"Ratner","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2016.11.005_bib38","first-page":"76","article-title":"Complete remission in two cases of adult T-cell leukemia\/lymphoma treated with hyper-CVAD: a case report and review of the literature","volume":"16","author":"Alduaij","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2016.11.005_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jjco\/hyr168","article-title":"Lymphoma study group of JCOG","volume":"42","author":"Tsukasaki","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib40","first-page":"227","article-title":"Final results of cooperative study of VEPA [vincristine, cyclophosphamide (Endoxan), prednisolone and Adriamycin] therapy in advanced adult non-Hodgkin\u2019s lymphoma: relation between T- or B-cell phenotype and response","volume":"12","author":"Shimoyama","year":"1982","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.1988.6.1.128","article-title":"Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin\u2019s lymphoma treated with VEPA or VEPA-M","volume":"6","author":"Shimoyama","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib42","first-page":"378a","article-title":"Japan Clinical Oncology Group phase II trial of second-generation \u2018LSG4 protocol\u2019 in aggressive T- and B-lymphoma: a new predictive model for T- and B-lymphoma","volume":"13","author":"Tobinai","year":"1994","journal-title":"Proc - Am Soc Clin Oncol, Meet"},{"key":"10.1016\/j.hoc.2016.11.005_bib43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A\u00a0new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma (ATL): Japan Clinical Oncology Group (JCOG) Study 9303","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.11.005_bib44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib45","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T\u00a0cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib46","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2016.11.005_bib47","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.11.005_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib49","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.11.005_bib50","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib51","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib52","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib53","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib54","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.hoc.2016.11.005_bib55","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib56","first-page":"5s","article-title":"Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL)","volume":"32","author":"O\u2019Connor","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.005_bib57","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","article-title":"Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma","volume":"155","author":"Berkowitz","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.hoc.2016.11.005_bib58","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.leukres.2011.12.004","article-title":"Phase II study on combination therapy with CHOP-Zenapax for HTLV-1 associated adult T-cell leukaemia\/lymphoma (ATLL)","volume":"36","author":"Ceesay","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2016.11.005_bib59","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","article-title":"Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicenter, dose-escalation study","volume":"3","author":"Ogura","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2016.11.005_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23937\/2469-5696\/1410010","article-title":"Lenalidomide in patients with relapsed or refractory HTLV-1 related adult T-cell leukemia\/lymphoma (ATLL)","volume":"2","author":"Phillips","year":"2015","journal-title":"Int J Blood Res Disord"},{"key":"10.1016\/j.hoc.2016.11.005_bib61","unstructured":"Fujiwara H, Ishida T, Nosaka K, et\u00a0al. Multicenter phase II study of lenalidomide in patients with relapsed adult T-cell leukemia-lymphoma. Oral session presented at: 57th Annual Meeting & Exposition of the American Society of Hematology. Orlando (FL), December 5\u20138, 2015."},{"key":"10.1016\/j.hoc.2016.11.005_bib62","series-title":"Annual report of nationwide survey 2013","author":"Hematopoietic Cell Transplantation in Japan","year":"2014"},{"key":"10.1016\/j.hoc.2016.11.005_bib63","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib64","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","article-title":"Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study","volume":"119","author":"Kanda","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib65","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","article-title":"Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study","volume":"120","author":"Ishida","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib66","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2004-11-4193","article-title":"Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma","volume":"105","author":"Okamura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.005_bib67","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bmt.2010.92","article-title":"Long-term outcomes after hematopoietic SCT for adult T-cell leukemia\/lymphoma: results of prospective trials","volume":"46","author":"Choi","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2016.11.005_bib68","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Ansell SM, Armand P, et\u00a0al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Oral session presented at: 56th ASH Annual Meeting and Exposition. San Francisco (CA), December 6\u20139, 2014.","DOI":"10.1182\/blood.V124.21.291.291"},{"key":"10.1016\/j.hoc.2016.11.005_bib69","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13302","article-title":"Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T\u00a0cell leukaemia\/lymphoma in a pilot study","volume":"169","author":"Suehiro","year":"2015","journal-title":"Br J Haematol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:03:59Z","timestamp":1760184239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816301733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0889858816301733"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adult T-cell Leukemia\/Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}